HOME

  ABOUT US
  MISSION
  EVENTS
  AWARDS
  USEFUL LINKS
  CHARITABLE ACTS
  DONATIONS
  NEWSLETTERS
  STACEY MEMORIAL
  GRANT REQUEST
  REVIEW COMMITTEE
  STORE

 

2017 AWARDS


NEW GRANT
Richard Gorlick, M.D.- Division Head- The University of Texas- MD Anderson Cancer Center

This study examined the safety of giving supplemental Bone Morphogenetic Protein-2 as a treatment to enhance the adhesion of allograft-host unions which is needed for recovery following limb salvag surgery for osteosarcoma patients.

Dr. Gorlick reports on findings! Click here to view his Article...

NEW GRANT
Richard Gorlick, M.D.- Division Head- The University of Texas- MD Anderson Cancer Center

HHLA2 is a new checkpoint inhibitor (a co T cell inhibitor) in the same family as PD-L1/PD-1 and this study examines its presence in osteosarcoma. The results of this study suggested some primary and most metastatic OS disease express this protein. This suggests this may be a relevant immunosuppressive mechanism in the OS tumor microenvironment.

Dr. Gorlick reports on findings! Click here to view his Article...

2016 AWARDS


NEW GRANT
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York

This study examined the prognostic significance of PD-L1 expression and immune cell(s) infiltration in osteosarcoma. It also started the investigation into the correlation of PD-1 and/or PD-L1 expression and immune cell infiltration with 5 year EFS (event free survival) outcomes.

Dr. Gorlick reports on findings! Click here to view his Article...

NEW GRANT
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York

This study attempted to better define the cellular origin of osteosarcoma using a mouse model. Osteoarcoma is believed to develop from a cell that is in the process of differentiating from a MSC (mesenchymal stem cell) to a pOB (preosteoblast).

Dr. Gorlick reports on findings! Click here to view his Article...

2015 AWARDS


CONTINUED FUNDING
Awarded in 2010 The Swim Across America Foundation of Nassau and Suffolk
“Stacey Leondis Fellowship at The Children’s’ Hospital at Montefiore”, Bronx, New York.

This annual support is given in Stacey's memory for a fellowship to further the osteosarcoma research effort in the laboratory of Dr. Richard Gorlick.

CONTINUED FUNDING
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York

Targeting the insulin-like growth factor receptor – With osteosarcoma clearly associated with normal human growth a focus of the Gorlick Laboratory has continued to be targeting this pathway with various drugs. Two pivotal clinical trials are ongoing now testing these drugs in sarcoma patients. A new concept targeting another member of this signaling pathway – IGF-2R- has yielded promising results.

CONTINUED FUNDING
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York

The study of GD2 directly led to a study of dinutuximab (ch14.18 antibody) by the Children’s Oncology Group in patients with recurrent osteosarcoma which opened to patient accrual on November 30, 2015. The study of GPNMB supported a study of glembatumumab vedotin which will be performed by the Children’s Oncology Group with planned activation in early 2016.

NEW GRANT
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York

Building upon work demonstrating the effectiveness of immune checkpoint inhibitors in the treatment of melanoma defined by genomic complexity, which is similarly present in osteosarcoma, the Gorlick Laboratory is initiating studies investigating the therapeutic relevance of these drugs. Effectiveness of these agents are driven by the presence of immune infiltrates as well as PD-1/PD-L1 expression which will be investigated with the support of the FOSTER foundation. These studies have the potential to identify these drugs as potentially effective in osteosarcoma driving clinical trials as previous studies have accomplished in the past.

CONTINUED FUNDING
Rachel L. Flynn, Assistant Professor, Department of Pharmacology & Experimental Therapeutics and Medicine, Division of Hematology and Medical Oncology, Boston University School of Medicine
Probing the Alternative Lengthening of Telomeres (ALT) Pathway in Osteosarcoma

In order for a normal cell to remain a cancer cell, a number of changes need to occur with one of them being maintaining the length of chromosomes, whose ends are called telomeres, through multiple cycles of cell division. Although most cancers stabilize their chromosomes through activating an enzyme called telomerase, others use a less well understood process called alternative lengthening of telomeres or ALT. The challenge with ALT is although drugs have been developed to inactivate telomerase, drugs have not previously been discovered that inhibit ALT. In work supported by the FOSTER foundation, the Flynn laboratory has shown that osteosarcoma uses ALT and coupled to how these cells correct DNA errors, a therapeutic vulnerability is revealed. Furthermore the Flynn Laboratory has discovered drugs which inhibit ALT which are needed to treat this class of tumors. The magnitude of this drug discovery yielded a publication in the high profile journal, Science. We anticipate with time this may yield new and improved treatments for osteosarcoma.

2014 AWARDS


CONTINUED FUNDING
Awarded in 2010 The Swim Across America Foundation of Nassau and Suffolk
“Stacey Leondis Fellowship at The Children’s’ Hospital at Montefiore”, Bronx, New York.

This annual support is given in Stacey's memory for a fellowship to further the osteosarcoma research effort in the laboratory of Dr. Richard Gorlick.

CONTINUED FUNDING
Rachel L. Flynn, Assistant Professor, Department of Pharmacology & Experimental Therapeutics and Medicine, Division of Hematology and Medical Oncology, Boston University School of Medicine
Probing the Alternative Lengthening of Telomeres (ALT) Pathway in Osteosarcoma

NEW GRANT
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York
Ganglioside GD2 as a Therapeutic Target for
Antibody-Mediated Therapy in Patients With Osteosarcoma

Targeting of ganglioside GD2, a glycosphingolipid on the cell surface of some tumors, with immunotherapy has resulted in improved outcomes for patients. In the current study, the expression pattern of GD2 was examined in osteosarcoma. Forty-four osteosarcoma samples were evaluated by immunohistochemistry, GD2 was expressed on all 44 osteosarcoma samples. Ganglioside GD2 is highly expressed on osteosarcomas. Clinical trials are needed to assess the efficacy of targeting GD2 in patients with osteosarcoma.

NEW GRANT
We have co sponsored this study with The Barbara Epstein Foundation and Swim Across America:
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York
Targeting Glycoprotein NMB with Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma


Targeting glycoprotein non-metastatic b (GPNMB) with the antibody-drug conjugate glembatumumab vedotin has demonstrated activity in patients with melanoma and breast cancer. The potential utility of targeting GPNMB in osteosarcoma was explored. All osteosarcoma cell lines demonstrated surface GPNMB expression. Glembatumumab induced cytotoxic effects in 74% (14/19) of osteosarcoma cell lines, and GPNMB protein levels correlated with glembatumumab in vitro cytotoxicity (r= -0.46, p= 0.04). GPNMB is expressed in osteosarcoma and targeting GPNMB with the antibody-drug conjugate glembatumumab vedotin demonstrates osteosarcoma cytotoxic activity. Clinical trials are indicated to assess the efficacy of targeting GPNMB in patients with osteosarcoma.


2013 AWARDS


Our supported studies for targeted therapies are entering clinical trials

NEW GRANT
Rachel L. Flynn, Assistant Professor, Department of Pharmacology & Experimental Therapeutics and Medicine, Division of Hematology and Medical Oncology, Boston University School of Medicine

Probing the Alternative Lengthening of Telomeres (ALT) Pathway in Osteosarcoma


CONTINUED FUNDING
Awarded in 2010 The Swim Across America Foundation of Nassau and Suffolk
“Stacey Leondis Fellowship at The Children’s’ Hospital at Montefiore”, Bronx, New York.

This annual support is given in Stacey's memory for a fellowship to further the osteosarcoma research effort in the laboratory of Dr. Richard Gorlick.


CONTINUED FUNDING
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York
New Clinical Trials for IGF1R Antibodies for the Treatment of Osteosarcoma
Our efforts have been instrumental in defining IGF-1R antibodies as relevant to the treatment of osteosarcoma.  These studies along with others continue to drive the clinical development of IGF-1R antibodies. A trial is ongoing in  Pediatric Oncology at the Memorial Sloan-Kettering Cancer Center investigating an IGF-1R antibody combination. A major study is being developed by the Children’s Oncology Group testing the effectiveness of IGF-1R antibody and it is anticipated patients will be able to enroll on this study shortly.  

New Clinical Trial for Arginine depletion therapy at MD Anderson Cancer Center for osteosarcoma

Argininosuccinate Synthetase Protein and Correlation with Novel Therapeutic ADI-PEG20 in Osteosarcoma
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York

The amino acid arginine is involved in protein synthesis and tumor metabolism and is essential for the growth of human cancer cells. Pegylated arginine deaminase (ADI-PEG20) is a novel therapy that lowers extracellular arginine levels and has shown evidence of clinical efficacy and low toxicity in patients with tumors lacking argininosuccinate synthetase (ASSl) protein expression.
 


NEW GRANT
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York
Targeted Therapy: CD47 as a Therapeutic Target for Osteosarcoma. CD47 a marker expressed on the surface of numerous tumors has been identified as a potential therapeutic target in a variety of malignancies. Based on those observations, initial studies were undertaken in osteosarcoma demonstrating the proteins frequent surface expression. Further studies are being supported investigating whether approaches targeting CD47 may be effective in the treatment of osteosarcoma.

2012 AWARDS


New Clinical Trial for Arginine depletion therapy at MD Anderson Cancer Center for Osteosarcoma

Argininosuccinate Synthetase Protein and Correlation with Novel Therapeutic ADI-PEG20 in Osteosarcoma
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York

The amino acid arginine is involved in protein synthesis and tumor metabolism and is essential for the growth of human cancer cells. Pegylated arginine deaminase (ADI-PEG20) is a novel therapy that lowers extracellular arginine levels and has shown evidence of clinical efficacy and low toxicity in patients with tumors lacking argininosuccinate synthetase (ASSl) protein expression.

CONTINUED FUNDING
The Osteosarcoma Genome Project
Marc Ladanyi, M.D., Paul Meyers, M.D. John Healey, M.D. - Memorial Sloan Kettering Cancer Center-New York, New York
Awarded in 2010: Osteosarcoma is not currently a focus of federally supported cancer genomics efforts such as The Cancer Genome Atlas. Our study will comprehensively screen the genome of both pediatric and adult Osteosarcomas for cancer causing mutations. Genomic technologies have advanced rapidly in recent years, making it possible to completely screen all genes in a given tumor sample for mutations. Screening of even a small number of samples of a given cancer type can yield important discoveries. The uniqueness of this study is that the analysis is coming from patients tumors at different stages of their disease i.e. not only biopsies.

CONTINUED FUNDING
Awarded in 2010 The Swim Across America Foundation of Nassau and Suffolk
“Stacey Leondis Fellowship at The Children’s’ Hospital at Montefiore”, Bronx, New York.

This annual support is given in Stacey's memory for a fellowship to further the osteosarcoma research effort in the laboratory of Dr. Richard Gorlick.

2011 AWARDS

NEW GRANT
Variable Expression of Argininosuccinate Synthetase Protein and Correlation with Novel Therapeutic ADI-PEG20 in Osteosarcoma
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York

The amino acid arginine is involved in protein synthesis and tumor metabolism and is essential for the growth of human cancer cells. Pegylated arginine deaminase (ADI-PEG20) is a novel therapy that lowers extracellular arginine levels and has shown evidence of clinical efficacy and low toxicity in patients with tumors lacking argininosuccinate synthetase (ASSl) protein expression. Previous studies have demonstrated the effectiveness of ADI-PEG20 in cancer cell lines with diminished or absent ASS1 protein including melanoma and hepatocellular carcinoma. Breast cancer and lung cancer cell lines, both of which frequently maintain strongly positive ASS1 protein expression, continued to proliferate in the presence of ADI-PEG20. ADI-PEG20 sensitivity has not been previously evaluated in osteosarcoma.

CONTINUED FUNDING
The Osteosarcoma Genome Project
Marc Ladanyi, M.D., Paul Meyers, M.D. John Healey, M.D. - Memorial Sloan Kettering Cancer Center-New York, New York
Awarded in 2010: Osteosarcoma is not currently a focus of federally supported cancer genomics efforts such as The Cancer Genome Atlas. Our study will comprehensively screen the genome of both pediatric and adult Osteosarcomas for cancer causing mutations. Genomic technologies have advanced rapidly in recent years, making it possible to completely screen all genes in a given tumor sample for mutations. Screening of even a small number of samples of a given cancer type can yield important discoveries. The uniqueness of this study is that the analysis is coming from patients tumors at different stages of their disease i.e. not only biopsies.

CONTINUED FUNDING
Awarded in 2010 The Swim Across America Foundation of Nassau and Suffolk
“Stacey Leondis Fellowship at The Children’s’ Hospital at Montefiore”, Bronx, New York.

This annual support is given in Stacey's memory for a fellowship to further the osteosarcoma research effort in the laboratory of Dr. Richard Gorlick.

2010 AWARDS

NEW GRANT
The Osteosarcoma Genome Project
Marc Ladanyi, M.D., Paul Meyers, M.D. John Healey, M.D. - Memorial Sloan Kettering Cancer Center-New York, New York

Awarded in 2010: Osteosarcoma is not currently a focus of federally supported cancer genomics efforts such as The Cancer Genome Atlas or the TARGET initiative. Our study will comprehensively screen the genome of both pediatric and adult Osteosarcomas for cancer causing mutations. Genomic technologies have advanced rapidly in recent years, making it possible to completely screen all genes in a given tumor sample for mutations. Screening of even a small number of samples of a given cancer type can yield important discoveries.

CONTINUED FUNDING
Awarded in 2010 The Swim Across America Foundation of Nassau and Suffolk
“Stacey Leondis Fellowship at The Children’s’ Hospital at Montefiore”, Bronx, New York.

This annual support is given in Stacey's memory for a fellowship to further the osteosarcoma research effort in the laboratory of Dr. Richard Gorlick.

Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York- Osteosarcoma Research Laboratory
Dr. Alex Chou- Pediatrics-Memorial Sloan Kettering Cancer Center-New York, New York
CONTINUED FUNDING
awarded in 2009: This study of  IGF-1R (insulin like growth factor), a highly active molecular pathway for osteosarcoma continues.

CONTINUED FUNDING awarded in 2009: We have co sponsored with the Stavros Niarchos Foundation a study being performed by Dr. Jennifer Perry at the Dana Farber Cancer Institute, Boston, Massachusetts. Her experiments will attempt to identify new pathways that are required for the viability and proliferation of p53/pRb-null osteosarcoma cells. 

  CONTINUED FUNDING awarded in 2009: This study is being performed by Dr. Erik Sampson at The University of Rochester, Rochester, New York. Dr. Sampson’s study is a preclinical evaluation of the c-Met inhibitor MK-8033 for the treatment of human osteosarcoma.

 

2009 AWARDS

 
NEW GRANT
The Swim Across America Foundation of Nassau and Suffolk
has created the “Stacey Leondis Fellowship at The Children’s’ Hospital at Montefiore”, Bronx, New York. This annual support will be given to the osteosarcoma research laboratory of Dr. Richard Gorlick in Stacey’s memory.

Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York- Osteosarcoma Research Laboratory
Dr. Alex Chou- Pediatrics-Memorial Sloan Kettering Cancer Center-New York, New York
CONTINUED FUNDING
awarded in 2009: This study of  IGF-1R (insulin like growth factor), a highly active molecular pathway for osteosarcoma continues.

NEW GRANT awarded in 2009: We have co sponsored with the Stavros Niarchos Foundation a study being performed by Dr. Jennifer Perry at the Dana Farber Cancer Institute, Boston, Massachusetts. Her experiments will attempt to identify new pathways that are required for the viability and proliferation of p53/pRb-null osteosarcoma cells. 

NEW GRANT awarded in 2009: This study is being performed by Dr. Erik Sampson at The University of Rochester, Rochester, New York. Dr. Sampson’s study is a preclinical evaluation of the c-Met inhibitor MK-8033 for the treatment of human osteosarcoma.

 

2008 AWARDS

CONTINUED FUNDING
Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York- Osteosarcoma Research Laboratory
Dr. Alex Chou- Pediatrics-Memorial Sloan Kettering Cancer Center-New York, New York
 
awarded in 2008: We have been co-funding with the Swim Across America Foundation of Nassau and Suffolk for the past 3 years, a study of  IGF-1R (insulin like growth factor), a highly active molecular pathway for osteosarcoma. We are very pleased to state that this study provided much of the basic science research needed for the initiation of a Phase II clinical trial of IGF-1R targeted therapy in osteosarcoma patients. A Phase III trial is currently in development based on promising results from the Phase II study. This is the first time that a targeted therapy for osteosarcoma will enter a Phase III clinical trial!

NEW GRANT awarded in 2008: We have co-sponsored with the Liddy Shriver Sarcoma Initiative a study at The University of Texas -MD Anderson Cancer Center, Houston, Texas for Dr. Nadezhda Koshkina's study of the role of CIP4 in osteosarcoma metastases.

NEW GRANT awarded in 2008: We have co sponsored with the Stavros Niarchos Foundation a study being performed by Dr. Anders Kolb at the AI Dupont Hospital for Children. His experiments will examine the effect of a monoclonal antibody against IGF-1R in a xenograft model.  This work seeks to identify the potential downstream targets in responsive tumors.  Dr. Kolb proposes to use gene array in a series of responsive and non-responsive tumors to determine the targets involved. This will allow optimization of patient selection for this therapy as well as the design of more effective treatment combinations.

 

2007 AWARDS

Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York- Osteosarcoma Research Laboratory
Dr. Alex Chou- Pediatrics-Memorial Sloan Kettering Cancer Center-New York, New York
NEW GRANT
awarded in 2007: The study is attempting to define which pathway(s) is used by osteosarcoma. Additionally it will analyze and prioritize which small molecule pathway inhibitor(s) could be used to treat osteosarcoma.

Peter Menges - Foster Board Member
Robert Panariello - Professional Athletic Performance Center, Garden City, New York
CONTINUED FUNDING
in 2007 for the physical conditioning and positive self image program designed especially for children upon completion of or during treatment for any pediatric cancer. Mark Weinblatt, MD, Pediatric Oncology Medical Director at Winthrop-University Hospital's Cancer Center for Kids referred the first two groups of participants in 2006.  CLICK HERE for News Article:

Professor Wei Zhu, PHD, New York-Applied Math and Statistics
Yue Zhang-PHD- Applied Math and Statistics
Renyuan Luo-Graduate Student-Applied Math and Statistics
SUNY at Stony Brook-New York

CONTINUED FUNDING in 2007 for the development of a "translational tool" (computer program) that can predict response to chemotherapy, for Osteosarcoma, prior to treatment using microarray genetic signatures.

 

2006 AWARDS

Chand Khanna- DVM, PhD, National Cancer Institute, Bethesda, Maryland - Research & Tumor Metastasis Section - Pediatric Oncology Branch
NEW GRANT  
for the testing of a "targeted" (limited toxicity) agent for osteosarcoma in an animal study for the National Institute of Health - Comparative Oncology - Pediatrics.

Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York- Osteosarcoma Research Laboratory
NEW GRANT
awarded for the upgrade of the genetic sequencer at the pediatric sarcoma lab. This upgrade is a four fold improvement in the labs SAGE sequencing capabilities. CLICK HERE for Thank You Letter

Peter Menges - Foster Board Member - Garden City, New York
NEW GRANT
in 2006 for the "trial" of a physical conditioning and positive self image program for children upon completion of therapy, of any pediatric cancer. CLICK HERE for News Article

Wei Zhu, PHD, SUNY at Stony Brook-New York, New York-Applied Math and Statistics
CONTINUED FUNDING
in 2006 to Dr. Zhu for the development of a mathematical algorithm for osteosarcoma. This program will attempt to correlate SAGE data to DNA microarray data to patient status.

Professor Wei Zhu, PHD,  New York-Applied Math and Statistics
Yue Zhang-PHD- Applied Math and Statistics
All from SUNY at Stony Brook-New York

CONTINUED FUNDING
in 2006 for the development of a “translational tool” (computer program) that can predict response to chemotherapy, for Osteosarcoma, prior to treatment using microarray genetic signatures.

Professor Wei Zhu, PHD,  New York-Applied Math and Statistics
Yue Zhang-PHD- Applied Math and Statistics
SUNY at Stony Brook-New York

CONTINUED FUNDING in 2006 for the analysis of metastatic osteosarcoma datasets using microarray and SAGE signatures.

 

2005 AWARDS

Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York- Osteosarcoma Research Laboratory
NEW GRANT
awarded for the compiling of microarray and SAGE datasets for metastatic Osteosarcoma.

Wei Zhu, PHD, SUNY at Stony Brook-New York, New York-Applied Math and Statistics
CONTINUED FUNDING
in 2005 to Dr. Zhu for the development of a mathematical algorithm for osteosarcoma. This program will attempt to correlate SAGE data to DNA microarray data to patient status.

Professor Wei Zhu, PHD,  New York-Applied Math and Statistics
Yue Zhang-PHD- Applied Math and Statistics
Neophytos Neophytou , Ph.D. Student, Department of Computer Science
All from SUNY at Stony Brook-New York

CONTINUED FUNDING
in 2005 for the development of a “translational tool” (computer program) that can predict response to chemotherapy, for Osteosarcoma, prior to treatment using microarray genetic signatures.

Professor Wei Zhu, PHD,  New York-Applied Math and Statistics
Yue Zhang-PHD- Applied Math and Statistics
SUNY at Stony Brook-New York

NEW GRANT awarded for the analysis of metastatic osteosarcoma datasets using microarray and SAGE signatures.

 

2004 AWARDS

Professor Wei Zhu, PHD,  New York-Applied Math and Statistics
Yue Zhang-PHD- Applied Math and Statistics
Neophytos Neophytou , Ph.D. Student, Department of Computer Science
All from SUNY at Stony Brook

NEW GRANT awarded for the development of a “translational tool” (computer program) that can predict response to chemotherapy, for Osteosarcoma, prior to treatment using microarray genetic signatures.

Wei Zhu, PHD, SUNY at Stony Brook, New York-Applied Math and Statistics
CONTINUED FUNDING in 2004 to Dr. Zhu for the development of a mathematical algorithm for osteosarcoma. This program will attempt to correlate SAGE data to DNA microarray data to patient status.


PHOTO UPDATE! -- Wei Zhu Group    Click here to view the photo...

 

2003 AWARD

Wei Zhu, PHD, SUNY at Stony Brook, New York-Applied Math and Statistics
NEW GRANT
awarded to Dr. Zhu for the development of a mathematical algorithm for osteosarcoma. This program will attempt to correlate SAGE data to DNA microarray data to patient status.


PHOTO UPDATE! -- Wei Zhu, PHD - SUNY at Stony Brook Click here to view the photo...

 

2002 AWARD

Dr. Richard Gorlick of The Sloan Kettering Memorial Cancer Center, New York-The Pediatric Sarcoma Research Laboratory
NEW GRANT awarded to Dr. Gorlick for the purchase of an Applied Biosystem Inc.-ABI Prism 3100 Genetic Analyzer. This new device will enable the laboratory to expedite and further analyze different genetic expressions and possible targets for additional research.


NEWS UPDATE! -- Dr. Gorlick reports on findings! Click here to view his letter...

 

 

Your help will make the difference. Make a Donation today